NDAORALCAPSULEPriority Review
Approved
Nov 2015
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NINLARO (ixazomib) is an oral proteasome inhibitor approved in 2015 for multiple myeloma treatment. It is the first and only oral proteasome inhibitor in its class, administered as a capsule in combination with lenalidomide and dexamethasone. The drug works by inhibiting proteasome activity in cancer cells, triggering apoptosis in multiple myeloma patients.
$312MPart D
PeakStable
3.2 years to LOEPeak-stage product with substantial Medicare Part D utilization supports a stable, mature commercial organization focused on market maintenance and optimization.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
Started Oct 2023
0Relapsed and Refractory Multiple Myeloma
A Survey on NINLARO Risk Management Plan (RMP) Material Utilization Among Pharmacists in Japan
Started Jun 2023
330 enrolled
Multiple Myeloma
A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma
Started Jun 2022
0Multiple Myeloma
A Study of NINLARO® in Chinese Adults With Multiple Myeloma
Started Oct 2021
72 enrolled
Multiple Myeloma
Study of Pomalidomide, Oral Dexamethasone and Ixazomib in Patients With Relapsed MM Who Have Received Lenalidomide
Started Jul 2021
60 enrolled
Multiple Myeloma
Worked on NINLARO at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.